Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Keeps The Approval Hitting Streak Alive With Another Infield Single
Tweet Send to a FriendGet Alerts HITK Hot Sheet
Price: $32.27 --0%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Trade HITK Now!
Needham & Company maintains a 'Buy' on Hi Tech Pharmacal (NASDAQ: HITK), PT $25.
Needham analyst says, "HITK has received tentative approval for its generic version of levofloxacin oral solution, equivalent to Johnson & Johnson’s (NYSE: JNJ)(not/rated) Levaquin, a broad-spectrum anti-infective. While the Levaquin solution market is tiny by JNJ standards at just $6.0MM, HITK currently has the only tentative approval with launch expected upon expiration of pediatric exclusivity in June. We assume there will be multiple competitors though in a “best case” scenario the product could generate $1.5MM in sales with potential EPS contribution up to $0.05 per annum. Levofloxacin is the latest in a string of small scale approvals that while yielding no near-term game changers, adds to current momentum in “base” generics to replace revenue lost due to removal of certain unapproved drugs over the past six quarters. Bottom line – core generics continue to receive a booster shot from recent approval streak..."
For more ratings news on Hi Tech Pharmacal click here and for the rating history of Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $21.58 yesterday, with a 52 week range of $16.69-$26.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Needham analyst says, "HITK has received tentative approval for its generic version of levofloxacin oral solution, equivalent to Johnson & Johnson’s (NYSE: JNJ)(not/rated) Levaquin, a broad-spectrum anti-infective. While the Levaquin solution market is tiny by JNJ standards at just $6.0MM, HITK currently has the only tentative approval with launch expected upon expiration of pediatric exclusivity in June. We assume there will be multiple competitors though in a “best case” scenario the product could generate $1.5MM in sales with potential EPS contribution up to $0.05 per annum. Levofloxacin is the latest in a string of small scale approvals that while yielding no near-term game changers, adds to current momentum in “base” generics to replace revenue lost due to removal of certain unapproved drugs over the past six quarters. Bottom line – core generics continue to receive a booster shot from recent approval streak..."
For more ratings news on Hi Tech Pharmacal click here and for the rating history of Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $21.58 yesterday, with a 52 week range of $16.69-$26.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- Deutsche Bank Takes Aegerion (AEGR) Price Target from $52 to $85
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
